Novartis' Pluvicto shown to reduce risk of progression or death by 28% in prostate cancer

Core Insights - Swiss drugmaker Novartis announced that its targeted radiotherapy treatment Pluvicto has demonstrated a 28% reduction in the risk of progression or death in patients with prostate cancer [1] Company Summary - Novartis is focusing on innovative treatments for cancer, with Pluvicto being a significant advancement in targeted radiotherapy [1] Industry Summary - The announcement highlights the ongoing advancements in cancer treatment, particularly in targeted therapies, which are becoming increasingly important in improving patient outcomes [1]